Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Positive Non-small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT06422546
What this trial is testing

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Beijing Cancer Prevention & Treatment Society 950
Not applicableStudy completedNCT04206787
What this trial is testing

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 72
Not applicableUnknownNCT01717105
What this trial is testing

Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

Who this might be right for
Metastatic Non-Small-Cell Lung Cancer
Grupo Gallego de Cancer de Pulmon 225
Early research (Phase 1)Active Not RecruitingNCT04001777
What this trial is testing

APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Ascentage Pharma Group Inc. 80
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT04563871
What this trial is testing

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Sehhoon Park 73
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)Ended earlyNCT05099549
What this trial is testing

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Who this might be right for
Squamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal Neoplasms+3 more
NKGen Biotech, Inc. 11
Not applicableStudy completedNCT02777567
What this trial is testing

KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)Ended earlyNCT00830245
What this trial is testing

Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Leptomeningeal CarcinomatosisNon-small Cell Lung Cancer
Clinical Research Center for Solid Tumor, Korea 20
Post-approval studies (Phase 4)UnknownNCT01665417
What this trial is testing

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Who this might be right for
EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
Betta Pharmaceuticals Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT01530334
What this trial is testing

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

Who this might be right for
Lung Cancer
AstraZeneca 61
Testing effectiveness (Phase 2)UnknownNCT04643847
What this trial is testing

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Who this might be right for
EGFR Positive Non-small Cell Lung CancerBrain Metastases
First People's Hospital of Hangzhou 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07256509
What this trial is testing

SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 120
Next Page